Coherus and Junshi Present Interim Results of Toripalimab in P-III JUPITER-06 Trial as 1L Treatment for Advanced Esophageal Squamous Cell Carcinoma at ESMO 2021

September 17, 2021 Auto Bot Clinical Trials, Coherus, Junshi, P-III, Toripalimab 0

Shots:

  • The P-III JUPITER-06 trial evaluates toripalimab + CT vs PBO + CT in a ratio (1:1) in 514 treatment-naive patients with advanced or metastatic ESCC
  • The study met its co-primary 1EPs i.e., improvements in PFS & OS compared to CT alone. At a prespecified interim analysis on Mar 22, 2021 @median follow-up of 7.4 &7.3mos.; m-OS (17.0 vs 11.0mos.); OS rates @1yrs. (66.0% vs 43.7%); grade ≥3 AEs (73.2% vs 70.0%) & fatal AEs were similar i.e., 8.2% & no new safety signals were observed
  • The companies plan to submit a BLA for toripalimab to the US FDA for the same indication in 2022. In early 2021, Coherus got in-licensed rights to develop and commercialize toripalimab in the US and Canada

Click here to­ read full press release/ article | Ref: Globe Newswire | Image: Coherus

The post Coherus and Junshi Present Interim Results of Toripalimab in P-III JUPITER-06 Trial as 1L Treatment for Advanced Esophageal Squamous Cell Carcinoma at ESMO 2021 first appeared on PharmaShots.